LX3305 250 mg capsule ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 161 | Familial benign chronic pemphigus | 1 |
161. Familial benign chronic pemphigus
Clinical trials : 5 / Drugs : 9 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-000373-80-FR (EUCTR) | 24/05/2018 | 13/03/2018 | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101 | Darier’s Disease or Hailey-Hailey Disease MedDRA version: 20.0;Level: LLT;Classification code 10011860;Term: Darier's disease;System Organ Class: 100000004850 MedDRA version: 20.1;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: LX3305 250 mg capsule Product Code: LX3305 INN or Proposed INN: None Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | Dermecular Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 1;Phase 2 | France |